{"id":"cm338-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, CM338 Injection prevents the interaction between PD-1 and its ligands, thereby releasing the brakes on the immune system and enhancing anti-tumor activity. This mechanism is thought to be particularly effective in treating various types of cancer.","oneSentence":"CM338 Injection is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:31:25.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT05186285","phase":"PHASE1","title":"Single Ascending Dose Study of CM338 in Healthy Volunteers","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2021-12-11","conditions":"Healthy","enrollment":66},{"nctId":"NCT05775042","phase":"PHASE2","title":"Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy","status":"RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2023-05-08","conditions":"IgA Nephropathy","enrollment":70},{"nctId":"NCT05371379","phase":"PHASE1","title":"Multiple Ascending Dose Study of CM338 in Healthy Volunteers","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-05-24","conditions":"Healthy Subjects","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":595852,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CM338 Injection","genericName":"CM338 Injection","companyName":"Keymed Biosciences Co.Ltd","companyId":"keymed-biosciences-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"CM338 Injection is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}